Seizure management in pediatric patients for the nineties

Pediatric Annals

Volumn 27, Issue 10, 1998, Pages 653-664

  Wolf, Steven M ^a,b   Ochoa, Juan G ^c   Conway Jr , Edward E ^b,d  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GABATRIL; LAMOTRIGINE; LORAZEPAM; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; TOPOMAX; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

BRAIN MAPPING; CHILD; DIET THERAPY; DISEASE CLASSIFICATION; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FOCAL EPILEPSY; HUMAN; PEDIATRICS; RECURRENCE RISK; REVIEW; RISK FACTOR; SEIZURE;

EID: 0031726929     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-19981001-09     Document Type: Review

References (46)

1. Berg A, Shinnar S. The contributions of epidemiology to the understanding of childhood seizures and epilepsy. J Child Neurol. 1994;2(Suppl):S19-S26.
2. Nordli D, Pedley T. Evaluation of children with seizures. In: Pediatric and Adolescent Medicine. Basel: Karger; 1995:67-77.
3. Berg B. The neurocutaneous disorders. In: Child Neurology: A Clinical Review, ed. 2. Philadelphia: J. B. Lippmcott; 1994:185-198.
4. Berg A, Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantative review. Neurology. 1991;41:965-972.
5. Shinnar S, Berg A. The risk of seizure recurrence after a first unprovoked afebrile seizure in childhood: An extended follow-up. Pediatrics. 1996;98:216-226.
6. Shinnar S, O'Dell C. Treating childhood seizures: When and for how long? Pediatr Adoles Med. 1995;6:100-110.
7. Maytal J, Shinnar S. Status epilepticus in children. Pediatr Adoles Med. 1995;6: 111-112.
8. Working Group on Status Epilepticus: Treatment of convulsive status epilepticus. JAMA. 1993;270:854-859.
9. Roger J, Bureau M, Dravet C, et al (eds). Epileptic Syndromes in Infancy, Childhood and Adolescence, ed 2. London: Libbey; 1992.
10. Camfield P, Camfield C. Febrile seizures. In: Shinnar S, Amir N, Branski D (eds). Pediatric and Adolescent Medicine. Basel: Karger; 1995:32.
11. Bethune P, Gordon KG, Dooley JM, Camfield C, Camfield P. Which child will have a febrile seizure? Am J Dis Child. 1993;147:35-39.
12. Camfield P, Camfield C. Febrile Seizures. In: Shinnar S, Amir N, Branski D (eds). Pediatric and Adolescent Medicine. Basel: Karger; 1995:32-38.
13. Verity CM, Gelding J. Risk of epilepsy after febrile convulsion: A national cohort study. Boston Med J. 1991;303:1373-1376.
14. Ellenberg JH, Nelson KB. Febrile seizures and later intellectual performance. Arch Neurol. 1978;35:187-197.
15. Ratcliffe JC, Wolf SM. Febrile convulsions caused by meningitis in young children. Ann Neurol. 1977;1:285-286.
16. Joffe A, McCormick M, DeAngelis C. Which children with febrile seizures need lumbar puncture? A decision analysis approach. Am J of Dis Child. 1983;137: 1153-1156.
17. Nelson KB, Ellenberg JH (eds). Febrile Seizures. New York: Raven Press; 1981.
18. Stores G. When dose an EEG contribute to management of febrile seizures? Arch Dis Child. 1991;66:554-557.
19. Wears RL, Luten RC, Lyons RG. Which laboratory tests should be performed on children with apparent febrile convulsions? An analysis and review of the literature. Pediatr Emerg Care. 1986;2:191-196.
20. Freenab JM. The best medicine for febrile seizures. N Engl J Med. 1992;327: 1161-1163.
21. Autret E, Billard C, Bertland P, et al. Double-blind randomized trial of diazepam versus placebo for prevention of recurrence of febrile seizures. J Pediatr. 1990; 117:490-495.
22. Knudsen FU, Vestermark S. Prophylactic diazepam or phenobarbitone in febrile convulsions: A prospective, controlled study. Arch Dis Child. 1978;53:660-663.
23. DeLorenzo RJ. Phenytoin: Mechanism of action. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995: 272-282.
24. Dodson WE. Phenytoin elimination in childhood: effect of concentration dependent kinetics. Neurology. 1980;30:196-199.
25. Kutt H. Phenytoin: Interaction with other drugs: clinical aspects. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:318-322.
26. Eldon MA, Loewen GR, Voigtman RE, et al. Pharmacokinetics and tolerance of fosphenytoin and phenytoin administered intravenously to healthy subjects. Can J Neurol Sci. 1993;20:s180.
27. Kutt H. Phenobarbital: Interactions with other drugs. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995: 390-399.
28. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SL, Ellenburg JH, Nelson KB. Phenobarbital for febrile seizures: effects on intelligence and on seizures recurrence N Engl J Med. 1990;322:364-369.
29. Prichard JW, Ransom BR. Phenobarbital: Mechanism of action. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:359-369.
30. Dodson WE. Carbamazepine and oxycarbazepine. In: Dodson WE, Pellock JM, eds. Pediatric Epilepsy: Diagnosis and Therapy. New York: Demos; 1993:308-311.
31. Bourgeon B. Valproic acid: Clinical use. In: Levy RH, Manson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:633-639.
32. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(suppl):s17-s22.
33. US Gabapentin Study Group, No 5: Gabapentin as add-on therapy in refractory partial epilepsy: a douhle-hlind, placebo-conrrolled, parallel-group study. Neurology. 1993;43:2292-2298.
34. Wolf SM, Shinnar S, Kang H, Ballaban-Gil K, Moshe SL. Gabapentin toxicity in children manifesting as behavior changes. Abstract presented at AES Dec. 1994. Epilepsia. 1996;36:1203-1205.
35. Leach MJ, Lees G, Riddal DR. Lamotrigine: Mechanism of action. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:861-869.
36. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology. 1993;43:693-696.
37. Richens A. Lamotrigine: Toxicity. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:897-902.
38. Ostergeard L, Gram L, Dam M, Tiagabine: In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:1057-1061.
39. Ben-Menachem E. Topiramate. In: Levy RH, Mattson RH, Meldrum, eds. Antiepileptic Drugs, Fourth Edition. New York: Raven Press; 1995:1063-1070.
40. Gram L, Sabers A, Dulac O. Treatment of pediatric epilepsies with gamma-vinyl GABA (vigabatrin). Epilepsia. 1992;33(Suppl.5):s26-s29.
41. Appleton RE. The role of vigabatrin in the management of infantile epileptic syndromes. Neurology. 1993;43:s26-s28.
42. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol. 1989;27(suppl 1):43S-45S.
43. Gibson JP, Yarington JT, Loudy DE, et al. Chronic toxicity studies with vigabatrin, a GABA-transminase inhibitor. Toxicol Pathol. 1990;18:225-238.
44. Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clin Bull. 1921;2:307-309.
45. Withrow CD. The ketogenic diet, mechanisms of anticonvulsant action. Adv Neurol. 1980;27:635-642.
46. Schwartz RH, Eaton J, Bower BD, Aynsley-Green A. Ketogenic diets in the treatment of epilepsy: short-term clinical effects. Dev Med Child Neurol. 1989;31: 145-151.